<DOC>
	<DOCNO>NCT02119234</DOCNO>
	<brief_summary>The study perform investigate effect space device pharmacokinetics CHF 5993 pMDI active ingredient administer without Aerochamber Plus Flow-vu antistatic VHC spacer single administration COPD patient . Moreover , general safety tolerability treatment evaluate .</brief_summary>
	<brief_title>Pharmacokinetics CHF 5993 pMDI With Without Spacer COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>COPD patient smoker exsmokers postbronchodilator FEV1 30 60 % predict value Positive serology HIV hepatitis Known respiratory disorder COPD Recent COPD exacerbation hospitalization COPD Treatment nonpermitted concomitant medication clinically relevant concomitant disease clinically relevant abnormal laboratory ECG parameter</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>